Abbott Biotechnology

AbbVie is a global, research-driven biopharmaceutical company formed in 2013 following its separation from Abbott Laboratories. The company focuses on developing advanced therapies for complex and critical conditions, particularly in immunology, oncology, neuroscience, and aesthetics. Its flagship product, Humira, was the world's top-selling drug for many years, and the company has successfully expanded its portfolio with newer blockbusters like Skyrizi and Rinvoq. AbbVie maintains a robust pipeline across various modalities, including small molecules and biologics, to address unmet medical needs in chronic diseases. Through strategic acquisitions like Allergan and ImmunoGen, the company has further diversified into medical aesthetics and targeted cancer treatments.